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A
VERY LARGE PERCENTAGE of patients suffering
from AIDS also suffer from neurological compli-
cations. Many of these problems can be attributed to
HIV-1 infection per se rather than being associated with
subsequent opportunistic infections or malignancies.
The precise characteristics of these neurological problems
depend on several factors, which include the severity of
the disease, the age of the patient, etc.
1,2 AIDS-related
neurological problems have been variously described
as the ‘AIDS dementia syndrome’ or the ‘HIV-1 related
cognitive–motor complex
3.’ These names provide a
reasonable description of the types of changes involved,
which include subcortical dementia, memory deficits
and motor problems. Neuropsychological testing and
imaging techniques can sometimes detect neurological
deficits in HIV-1-positive individuals, even prior to the
full development of AIDS (Ref. 4). Complications of the
CNS are particularly notable in children who are in-
fected with HIV-1 perinatally and exhibit rapidly pro-
gressing disease. Up to 80% of such children display
neurological symptoms, including slow development,
motor deficits and impaired brain growth
5.
Neuropathological and imaging studies have demon-
strated a variety of complex changes in the brain that
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The major types of cells targeted by HIV-1 following infection are
CD4-positive dendritic cells in the skin and mucosa, and lympho-
cytes and resident macrophages in many tissues, including the brain
(microglia). The first types of cells to become infected appear to be
macrophages and dendritic cells, with T lymphocytes becoming the
main targets later in the disease as increasingly virulent strains of
HIV-1 emerge. It is this latter phase of the disease that is associated
with the accelerated destruction of the immune system
a.
How does the HIV-1 virus infect these cells? A key discovery in
the understanding of this process was the identification of the cellu-
lar receptors for HIV-1 binding and entry. Enveloped viruses such as
HIV-1 need to fuse their lipid membranes with that of their target
cells to allow the core of the virus to enter the cell for replication. In
the case of HIV-1 and related lentiviruses (for example, HIV-2, SIV
and FIV) this fusion is triggered by the binding of the main viral en-
velope glycoprotein, gp120, to receptors on the cell surface
b. Evidence
was originally presented that the CD4 molecule could act as an HIV-
1 receptor. However, it rapidly became apparent that binding to
CD4 could not adequately explain many of the characteristics of
HIV-1 infectivity, such as the fact that different strains of HIV-1
showed preference for different types of cells (‘tropism’) and the fact
that CD4 could not support HIV-1 binding and entry when found
alone in cells
a. In 1996, several groups made a startling discovery and
demonstrated that HIV-1 infection and the cell selectivity shown by
different strains of HIV-1 was based on their use of different ‘co-
receptors’ that functioned in association with CD4 to mediate HIV-1
binding and entry. The big surprise was the nature of these molecules:
G-protein-coupled receptors (GPCRs) for chemokines (reviewed in Refs
a–e). Chemokines (chemotactic cytokines) are a family of related
small proteins (8 to 10 kD, 90–125 amino acids with 20 to 70%
amino-acid homology to one another) that have been shown to be
essential for various forms of information transfer and signaling
between different types of immune cells
f. Chemokines mediate phe-
nomena such as leukocyte chemotaxis and cell-surface adhesion,
which are essential in directing these cells to sites of infection. This
is rather an oversimplification, which is reflected by the very large
number of chemokines that have been shown to exist (at least 30 so
far)
f,g and the fact that the size of this family is growing almost daily.
Chemokine structure and effects indicate that they fall into four
families, the two largest of which, at present, are the a and b chemo-
kine families (Table I)
f,g. Chemokines in these families are typified by
the presence of four cysteine residues in their sequences. In a chemo-
kines, such as stromal-derived factor 1a (SDF1a), one amino acid sep-
arates the first two cysteines (CXC) whereas in the b-chemokines such
as RANTES (regulated on activation normal T expressed and secreted),
the first two cysteines are next to one another (CC). Two other emerg-
ing ‘families’ of chemokines can be typified by fractalkine, in which
the first two cysteines are separated by three amino-acid residues
(CXXXC), and lymphotactin, which has only two cysteines in total.
These different families of chemokines exert their effects by activating
a family of GPCRs (Table I). Activation of chemokine receptors can
produce a variety of signaling events, such as the mobilization and
influx of Ca
21 [there are many examples of this (see Refs f–i)] and also
including activation of pathways involving small G proteins
j, tyrosine
kinases
k,l, PI3 kinase
m,n, components of the mitogen-activated protein
kinase pathway
o–q and a variety of ion channels
o,r. Effects on down-
stream intracellular signals such as the AkT kinase
s and the transcrip-
tion factor nuclear factor-kB (Ref. t)have also been reported. a-Chemo-
kines activate CXCR1–5, b-chemokines activate the CCR1–10 and
fractalkine activates CX3CR1. However, this list is certainly incomplete
and there are already many ‘orphan’ chemokine receptors in the lit-
erature whose ligands await identification. It was shown that for the
infection of macrophages by M-tropic (that is, macrophage selective)
strains of HIV-1 to take place, CD4 and the chemokine receptor,
CCR5, are required, and also that CD4 is used in combination with
the CXCR4 for the infection of T lymphocytes by T-tropic (that is,
T-lymphocyte selective) strains of HIV-1 (Refs c–g,i). The HIV-1 enve-
lope protein is initially produced as a large precursor, gp160, which is
cleaved by a protease into two subunits, gp120 and gp41, that remain
non-covalently associated. The cell-surface protein, gp120, appears to
bind directly to chemokine receptors at diverse sites, the V3 loop of
this protein being a particularly important determinant of tropism.
Mutual interactions between gp120, chemokine receptors and CD4
are thought to result in conformational changes that result in exposure
of the fusion domain of the viral envelope protein, gp41, and sub-
sequent viral fusion and entry
b,j,u. Some virally infected cells even-
tually die through apoptotic mechanisms, although some, such as
microglia, are relatively resistant
v.
The mutual receptor interactions between gp120 and chemokines
could be of great significance for the development of HIV-1 infection
and could also have considerable therapeutic implications. It appears
that chemokines and gp120 bind to distinct but ‘overlapping’ sites on
chemokine receptors
w–y. Competition between chemokines and gp120
has been observed directly in biochemical binding assays
z,aa–cc, as
well as in functional assays
r,ee,ff, suggesting that chemokine receptor
agonists and antagonists could potentially directly block HIV-1
interactions with chemokine receptors and its entry into cells
gg,hh.
Furthermore, a chemokine agonist, such as SDF1a, can transiently
downregulate its chemokine receptor (CXCR4), presumably by endo-
cytotic mechanisms, thus providing another potential mechanism
for functional competition
dd–ff. A large number of studies have now
Box 1.HIV and the immune system
TABLE I. Chemokine receptors and some of their ligands
Receptor Ligand(s)
CX chemokine receptors
CXCR1 IL8 and GCP2
CXCR2 IL8, GROa/b/g, NAP2, ENA78 and
GCP2
CXCR3 IP10 and Mig
CXCR4 SDF1a
CXCR5 BCA1/BLC
CC chemokine receptors
CCR1 RANTES, MIP1a, MCP2 and MCP3
CCR2 MCP1, MCP2, MCP3 and MCP4
CCR3 Eotaxin, eotaxin 2, RANTES, MCP2,
MCP3 and MCP4
CCR4 MDC, TARC, RANTES, MIP1a and
MCP1
CCR5 RANTES, MIP1a and MIP1b
CCR6 LARC/MIP3a/exodus
CCR7 ELC/MIP3b
CCR8 I309
CCR9/10 MCP1 and MIP1b
CX3CR1 Fractaline/neurotactin
Abbreviations: BCA1, B-cell attracting chemokine 1; BLC, B-lymphocyte chemo-
attractant; ELC, (Epstein–Barr-virus-induced gene 1)-ligand chemokine; ENA78,
epithelial-cell-derived neutrophil-activating peptide 78; GCP2, granulocyte chemo-
tactic protein; GRO a/b/g, growth-regulated oncogene a/b/g; IL8, interleukin 8;
IP10, interferon-inducible protein 10; LARC, liver- and activation-regulated chemo-
kine; MCP, monocyte chemoattractant protein; MDC, macrophage-derived protein;
Mig, monokine induced by interferon g; MIP, macrophage inflammatory protein;
NAP2, neutrophil-activated peptide 2; RANTES, regulated on activation normal T
expressed and secreted; SDF1a, stromal-derived factor 1a; TARC, thymus- and
activation-regulated chemokine.TINS Vol. 22, No. 10, 1999 473
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demonstrated inhibition of HIV-1 infection in vitro by different
chemokine receptor agonists and antagonists
ee–ll. Thus, it might also
be predicted that chemokines would be able to reduce HIV-1 infec-
tion in vivo. This appears to be the case in that individuals who have
high circulating levels of some chemokines show a reduced suscep-
tibility to HIV-1 infection
mm,nn. Furthermore, it has also been shown
that several individuals carry a mutation (a 32 amino-acid deletion)
that results in the synthesis of a nonfunctional CCR5 receptor.
Individuals who are homozygous for these mutations show a greatly
reduced likelihood of being infected with HIV-1 and heterozygotes
can show a slower time course of infection
nn.
It is interesting to note that gp120 does not only bind to chemokine
receptors but it can also elicit signals through them: in some ways it
can act as an agonist
k,o,pp,qq. Thus, binding of both gp120 and chemo-
kines to the same receptors can produce G-protein-mediated agonist-
like effects on the generation of second messengers such as Ca
21 and
mitogen-activated protein (MAP) kinase, although these agonist effects
are not apparent in all systems
r. As the mode of interaction of gp120
and chemokines with chemokine receptors is not exactly the same
w–y,
the patterns of signaling produced by the two could well be different
in certain key respects. It is not clear at this point whether receptor-
mediated second-messenger effects are important in the mechanisms
underlying the infection and death of cells produced by HIV-1 or
whether chemokine-mediated second-messenger actions are of impor-
tance in inhibiting the effects of HIV-1. Inhibition of HIV-1 binding
by chemokines appears to be sufficient to inhibit HIV-1 infection in
some paradigms in vitro. Several studies have been able to dissociate
the inhibitory binding effects of chemokines from their ability to
signal
w,y,hh. Furthermore, chemokine antagonists that bind but do not
signal, can also inhibit HIV-1 effects
gg–ii. Nevertheless, second messen-
gers produced by chemokines and gp120 could yet prove to be impor-
tant for their mutual interactions. For example, the ability of the
CCR4 selective chemokine, macrophage-derived chemokine (MDC),
to inhibit the infectivity of both T- and M-tropic strains of HIV-1 might
involve effects of the chemokine downstream of HIV-1 binding
rr.
Similarly, downstream events could be important in the effects of
chemokines and gp120 in the brain. 
Although the idea that CCR5 and CXCR4 are the major co-receptors
for HIV-1 infection revolutionized our thinking on this subject com-
pletely, important details of this process continue to emerge. The pre-
cise determinants of HIV-1 tropism in vivo are clearly very complex
and continue to be defined. Thus, some strains of HIV-1 exhibit dual
tropisms and others can also use chemokine receptors in addition to
CCR5 and CXCR4. To date, at least  ten chemokine receptors includ-
ing CCR3, CCR2b, CCR8 and CX3CR1, as well as the orphan chemo-
kine receptors GPR15 (BOB), STRL33 (BONZO), GPR1 and the virally
encoded receptor, US28, have been shown to act as co-receptors for
HIV-1 infection under some circumstances (Table II)
a. These might be
very important in certain instances, such as HIV-1 effects in the brain
where CCR3 appears to be a major co-receptor for HIV-1 infection
of microglia
ss. It has also been reported that individuals that carry mu-
tations in the gene for CCR2 exhibit a slowed progression of HIV-1-
associated disease
nn, which further illustrates the complexity of the
situation. Furthermore, some strains of HIV-2 and SIV have been
shown to be able to infect cells without requiring participation of the
CD4 molecule
a,aa,tt. In these cases, chemokine receptors might be the
only receptors involved. Such observations suggest that chemokine re-
ceptors were the original receptors for HIV-1-like viruses from the
evolutionary point of view and that the use of CD4, which can often
increase the affinity of the interaction, is a later development.
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TABLE II. Chemokine-receptor-family members known to
function as receptors in HIV-1 and SIV entry into the brain
Receptor Ligand(s) Location
Major receptors
CCR3 Eotaxin, MCP3, MCP4 Eosinophilis, microglia
and RANTES and Th2 cells
CCR5 MIP1a, MIP1b and Monocytes and T cells
RANTES
CXCR4 SDF1a Lymphocytes,  
macrophages, neurons
and astrocytes
BOB/GPR15 Unknown T cells and colon
Bonzo/STRL33/TYMSTR Unknown T cells, monocytes and 
placenta
Minor receptors
CCR2 MCP1 and MCP3 Monocytes and T cells
CCR8 I309 Monocytes and 
thymocytes
CX3CR1 (V28) Fractaline/neurotactin Lymphocytes, neurons
and microglia
GPR1 Unknown Macrophages
APJ Unknown Brain
Abbreviations: MCP, monocyte chemoattractant protein; MIP, macrophage inflam-
matory protein; RANTES, regulated on activation normal T expressed and secreted;
SDF1a, stromal-derived factor 1a.474 TINS Vol. 22, No. 10, 1999
are associated with HIV-1 infection and suggest mul-
tiple pathologies
4–6. Interestingly, retroviruses that are
related to HIV-1 (lentiviruses), such as SIV (Ref. 7) and
FIV (Ref. 8), cause somewhat similar changes in the CNS
of monkeys and cats, respectively, suggesting that the
mechanisms underlying the CNS-associated pathol-
ogies are preserved across species. HIV-1-related changes
in the brain include the formation of giant cells, wide-
spread reactive astrocytosis and white-matter pallor
5,6.
There is also evidence for dendritic pruning, and neur-
onal and glial loss in some cases. The loss of neurons
and glia has been associated with apoptotic profiles in
the brains of both adults and children
7–12. However,
despite the fact that many observations have been made
on the neurological consequences of HIV-1 infection,
the precise mechanisms that underlie damage to the
brain and produce the death of neurons, in particular,
are unclear. Indeed, there are several very puzzling
things that require explanation. For example, we know
that the destruction of immune cells subsequent to
HIV-1 infection is associated with replication of the
virus in these cells. However, there is no compelling
evidence that HIV-1 and related viruses can replicate
in neurons
13,14. Indeed, the number of productively in-
fected cells in the brain (mainly microglia) in associ-
ation with HIV-1 infection is relatively small in com-
parison with the wide ranging pathology observed.
Thus, the mechanistic basis for neuronal apoptosis
remains elusive (see below).
Several far-reaching observations made over the past
few years have served to revolutionize completely our
understanding of how HIV-1 infects cells of the immune
system (see Box 1). These discoveries have highlighted
the key roles of chemokines and their receptors in this
process. How do these discoveries help us to understand
the neurological aspects of HIV-1 infection?
HIV-1 and the brain
It is thought that HIV-1 enters the brain in associ-
ation with infected macrophages soon after infection
15.
Following this entry it would be simple if the virus
then entered and replicated in neurons as it does in
immune cells, which leads to their ultimate apoptotic
death. However, as stated above, this is clearly not the
case. HIV-1 and related viruses do not replicate in neur-
ons. Furthermore, HIV-1 only infects astrocytes and
oligodendrocytes non-productively
1,16–18. Nevertheless,
it is clear that effective replication of the virus does occur
in the CNS and that the brain is considered to be a sig-
nificant reservoir for HIV-1 following infection
1,15,18. The
cells in the brain that are infected by HIV-1 successfully
are resident microglia, as well as infected macrophages
that are thought to migrate into the CNS. Histological
studies have demonstrated frequently the existence of
HIV-1-related proteins in microglia and multinucleate
giant cells, which result from the fusion of microglial
cells by virus particles
2,19,20.
As only relatively few cells in the brain harbor the
replicating virus it is not immediately obvious how such
widespread pathology is produced. It seems as though
some type of amplification mechanism is required to
explain these observations. Studies have shown that
following the development of HIV-1 infection of the
brain, activated microglia and astrocytes are observed
in combination with neuronal lesions
1,2,5,6,16,18. Thus, it
has been suggested that damage to neurons of the CNS
could occur through an ‘indirect’ mechanism. It has
been considered likely that one or more factors might
be released from activated microglia and activated
astrocytes, and that these might be directly toxic to
neurons or be involved in a cascade of interacting cellu-
lar events that ultimately lead to the release of neuro-
toxins
1,21. There have been many suggestions as to the
types of molecules that might mediate such neuro-
toxicity following HIV-1 infection. These include a
variety of cytokines; platelet-activating-factor and
arachidonic-acid derivatives; radicals, such as O2
2 and
NO; and glutamate
1,16,18,22. Indeed, there is good evi-
dence that glutamate-mediated excitotoxicity has a
role at some point along the pathway, which has led
to the use of excitatory-amino-acid antagonists in
clinical trials for AIDS-related dementia
1,16,18,23,24. Other
evidence implies a role for HIV-1-derived proteins in
neurotoxicity. Studies in vitro have demonstrated that
the viral envelope glycoprotein, gp120, can be shed by
HIV-1 and might also be found in the brain
1,16,18. It has
also been shown that gp120 can cause the activation 
of microglia and astrocytes
1,16,18,25 and that it is toxic 
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Fig. 1. Chemokine receptors on rat hippocampal neurons and the effects produced when
they are activated. Rat hippocampal neurons possess a wide range of functional chemokine
receptors, which include CXCR4 and CCR5. These receptors mediate direct effects of
chemokines and gp120 on neuronal activity and survival
32. (A) illustrates immunocytochem-
ical localization of CXCR4 (left) and CCR5 (right) on cultured rat hippocampal neurons
obtained from rat embryos. Note that CXCR4 is much more widely distributed in neuronal
processes than CCR5. (B) illustrates effects of the CXCR4 agonist, SDF1a (stromal-derived factor
1a), and the CCR5 agonist, RANTES (regulated on activation normal T expressed and
secreted), on intracellular Ca
21 levels, [Ca
21]i, in single rat hippocampal neurons. (C) illus-
trates the effects of CXCR4-specific (HIV-1) gp120 and CCR5-specific (SIV) gp120 on [Ca
21]i
in single rat hippocampal neurons
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to neurons when applied in culture
23–29. Thus, gp120
could have a significant role at several key points in
HIV-1 infection of the brain. Importantly, transgenic
mice that overproduce gp120 exhibit brain pathology
that is in many ways similar to that seen in the brains
of HIV-1-infected patients
30. Toxic roles for other HIV-
1-derived proteins have also been suggested
1.
Given what is known about the interactions of gp120
with immune cells, and the role of chemokine receptors
in particular (Box 1), it is important to understand the
nature of any chemokine receptors that exist in the
brain. Do brain cells possess chemokine receptors and
if so, which cells? Furthermore, can chemokines regulate
neuronal functions either directly or indirectly? Finally,
are central chemokine receptors involved in the effects
of HIV-1 in the brain?
Chemokine receptors in the brain
It is now clear that all the major cell types in the
brain (neurons, glia and microglia) possess chemokine
receptors
31. Microglia have large numbers of several types
of chemokine receptors. The presence of chemokine re-
ceptors on astrocytes is more controversial, although it
is likely that at least some subpopulations have modest
numbers of receptors. Perhaps surprisingly, neurons ap-
pear to be very well endowed with a variety of interest-
ing chemokine receptors
32. The possible physiological
reasons for this will be discussed below. It should be
noted that evidence indicating the presence of chemo-
kine receptors on neurons is generally based on the
detection of mRNA and occasionally protein. Few data
on functional consequences of the presence of these
receptors have been published, although establishing
their function will clearly be beneficial.
a-Chemokine receptors
Several studies have demonstrated the existence of
a-chemokine receptors in the nervous system (Fig. 1),
particularly CXCR2, CXCR4 and CXCR5. Horuk et al.
33
showed that although they could not detect CXCR1 in
the human CNS, CXCR2 was widely distributed on
neurons in the brain and spinal cord. This included the
hippocampus, hypothalamus, cerebellum, midbrain
and spinal cord, including projections from dorsal-
root ganglia. CXCR2 was also identified in cultures of
human fetal neurons
34, in cultures of rat hippocampal
pyramidal neurons
32 and in hNT cells, a human cell
line with some differentiated neuronal properties
34. In-
terestingly, CXCR2 has also been found to be associated
with dystrophic neuritic plaques in Alzheimer’s dis-
ease
35. Lavi et al.
36 found CCR4 to be widely distributed
throughout the human CNS, primarily in neurons and
microglia, as well as some reactive astrocytes, as also de-
scribed in mice by Tanabe et al.
37,38 Westmorland et al.
39
demonstrated that CXCR3 was absent from the macaque
CNS but found that CXCR4 was abundant in neurons
in the cortex and hippocampus, as well as in glial cells
throughout the brain. CXCR4 was also found to be
localized on microglia and neurons in the cortex, and
in the basal ganglia of the brains of children with AIDS
(Ref. 40). The widespread distribution of CXCR4 has also
been noted in monkey
41,42, rat
43,44, mouse
45 and bovine
46
brain, as well as in cultured rat hippocampal pyramidal
neurons
32 and the hNT cell line
34. Finally, the CXCR5 has
also been shown to be present throughout mouse and
rat brain
47,48. This receptor is also found in NG108-15
neuroblastoma 3 glioma cells but not in C6 gliomas,
which prompts the suggestion that it is mostly present
in neurons rather than glia
47. However, this possibility
remains to be demonstrated.
b-Chemokine receptors
Receptors for b-chemokines are also found in abun-
dance in the nervous system (Fig. 1). CCR1 has been
found in cultures of murine astrocytes
49 as well as in
cultures of rat hippocampal pyramidal neurons
32 and
hNT cells
34. CCR3 has been found to be widely distrib-
uted in brain microglia from humans
19 and macaques
42,
as well as in some astrocytes and populations of neur-
ons
41. Oligodendrocytes were CCR3-negative
42. CCR5
was found in neurons in some parts of macaque and
human brain, and also in glia and microglia
38,42,50. CCR5
was also shown to be present in the hNT cell line
34
and in cultured rat hippocampal pyramidal neurons
32.
Interestingly, levels of CCR5 are increased following
excitotoxic injury
25. CCR8 has been detected in ‘brain-
derived’ cells
51, and CCR9/10 has been shown to exist in
rat brain, using northern-blot analysis
52, and in cultures
of rat hippocampal pyramidal neurons
32.
Other receptors
A particularly interesting chemokine receptor is
CX3CR1, previously known as V28 (Refs 53,54). This is
the receptor for the novel chemokine, fractalkine
55.
The receptor was found, using northern-blot analysis,
in most parts of the brain and spinal cord of humans
and rats
53,54, although the types of cell on which it was
found were not identified originally. However, CX3CR1
was shown subsequently to exist in cultured rat hippo-
campal neurons
32 and glial cells
38, and is present in
large numbers in microglia
56,57. Fractalkine synthesis in
the brain appears to occur primarily in neurons
56,57. It
has a very unusual structure, which contains a unique
CX3C motif, and appears to be synthesized as a mem-
brane-bound glycoprotein with the extracellular chemo-
kine moiety attached to a transmembrane mucin-like
stalk
58,59. Cleavage can occur and causes the release of
soluble forms of the chemokine. Fractalkine and its 
receptor have been shown to mediate leukocyte migr-
ation
55, as do other chemokines, but, in addition, it
also mediates leukocyte adhesion – an effect that can
occur in the absence of signaling. Rat hippocampal
neurons appear to synthesize both CX3CR1 and frac-
talkine, which raises the possibility that this chemokine–
receptor pair could subserve a similar function in the
nervous system
32. In addition, it is also possible that
fractalkine or CX3CR1, or both, mediate communication
between neurons and microglia
57.
Some orphan chemokine receptors have been found
in the CNS but further chemokine receptors remain to be
identified
60,61. Finally another molecule, known as the
Duffy antigen, which binds chemokines but probably
has no known signaling function and is not a G-protein
coupled receptor (GPCR) or an HIV-1 co-receptor, has
also been found in the brain, and is particularly localized
to Purkinje cells
31.
HIV-1 and brain chemokine receptors
A large number of chemokine receptors can po-
tentially function as co-receptors for HIV-1 infection
(Box 1)
62. Several of these, including CXCR4, CCR3,
CCR5, CCR8, CCR9/10 and CX3CR1, have been shown
to exist in the brain or on brain-derived cells. An impor-
tant question, therefore, is whether these have a role in
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HIV-1-associated brain pathology. It is certainly likely
that infection of brain microglia involves the same types
of mechanisms as infection of peripheral immune cells.
In this case, however, the importance of CCR3 as a co-
receptor, in addition to CCR5, has been suggested
19.
Clearly, HIV-1 replicates in brain microglia and related
cells. These microglia could release potentially neuro-
toxic factors or substances that activate astrocytes and
lead to the further release of toxic substances
1,16,18. Such
possibilities have been widely discussed; but what about
the chemokine receptors found on neurons themselves,
what role do they have? One possibility to consider is
that although HIV-1 does not replicate in neurons,
gp120, which binds to chemokine receptors, might still
be an important factor in producing HIV-1-related
pathology. There are several reasons for thinking this.
In vitro evidence suggests that gp120 might be shed from
cells in the brain where HIV-1 is replicating actively
1,16,18.
This gp120 would potentially be available to interact
with chemokine receptors on neurons and other cells.
Furthermore, there is much evidence to show that
gp120 can produce neurotoxicity. As discussed above,
transgenic mice that overproduce gp120 display many
of the features of HIV-1-related brain pathology
30, in-
cluding widespread astrocytosis, microglial activation,
vacuolization of neuronal dendrites, and loss of syn-
apses and neuronal subpopulations. Obviously, such
experiments do not indicate the cells in the brain on
which gp120 acts, but they do strongly support the
possibility that it might be a neurotoxic factor. There
are also data suggesting that binding of gp120 to neur-
ons might initiate apoptotic neuronal death directly.
These studies have shown that addition of gp120 [both
M and T tropic (macrophage selective and T-lymphocyte
selective)] to primary brain neuronal cultures, or specific
neuronal cell lines, produces clear apoptotic death over
a period of a few days
19,23,27–29,44,63. It is possible, therefore,
that gp120 might produce neuronal death by a direct
effect on neurons in addition to indirect routes. A recent
study on the apoptosis induced by infection of primary
brain cultures with different HIV-1 isolates has also
shown that the type of envelope protein synthesized by
the viruses is a major determinant of neurodegenerative
mechanisms associated with HIV-1 infection in vitro
64.
Any interaction between gp120 and neurons would pre-
sumably occur through binding to chemokine receptors,
with the possible assistance of other molecules
65, as it
does in immune cells (Box 1).
As the data suggesting that gp120 can kill neurons
by indirect routes have been extensively reviewed else-
where
1, this article will discuss the possibility that it
might also do so through direct effects on neuronal
chemokine receptors. Why should binding of gp120
to neuronal chemokine receptors trigger neuronal
death? Given the published data showing that gp120
can not only bind to chemokine receptors but can also
initiate signaling through these interactions (Box 1,
Fig. 1)
34,63,66,67, one possibility is that gp120 binding
initiates aberrant signaling that triggers neuronal
apoptosis. Evidence is accumulating that gp120 can
produce intracellular signals in neurons (Fig. 1)
34,63.
These signals might be variants on those that are pro-
duced by chemokines themselves when acting at the
same receptors. This could lead to detrimental conse-
quences for neuronal function, perhaps in an analo-
gous manner to the effects of signaling through the
oncogenic chemokine receptor encoded by the Kaposi’s
sarcoma associated herpes virus (also known as HHV-8),
which produces aberrant growth-promoting signals
(Box 2)
68,69.
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It is interesting to note that the survival–growth-promoting, anti-
apoptotic potential of chemokines has been recognized and used by
certain strains of viruses. One of the major goals of every virus must
be to preserve the health of the host cell in which it replicates, for
once that cell is dead it is no longer of any use. Thus, viruses have
devised various strategies to protect their cellular hosts. Several
viruses seem to have targeted chemokines and their receptors with
such a strategy. For example, the human cytomegalovirus, a member
of the herpes virus family, encodes a chemokine receptor (designated
US28) that can bind the chemokine, macrophage inflammatory
protein 1a (MIP1a; Ref. a). Herpes virus Saimiri encodes a chemokine
receptor that is related to the interleukin 8 (IL8) receptors, CXCR1
and CXCR2, and it has been suggested that it could have some pro-
liferative role in virally mediated cell transformation
b,c. Furthermore,
HHV-8 encodes a fascinating chemokine receptor that is related to a
receptor encoded by herpes virus Saimiri
d–f. HHV-8 is the virus respon-
sible for the producing both Kaposi’s sarcoma and Castelman disease.
In this case, the receptor produced by HHV-8 is constitutively active
and does not require an agonist to produce active signaling. The
receptor has oncogenic and angiogenic properties, stimulating cell
proliferation in association with the activation of a number of cell-
signaling pathways, which include the JUN N-terminal protein kinase
(JNK), stress-activated protein kinase (SAPK) and p38 kinase, which
are members of the mitogen-activated protein kinase pathway.
Amazingly, HHV-8 also encodes a number (probably three) of chemo-
kines (‘viralkines’) that are related in structure to MIP1a (Refs g,h).
vMIP-II appears to activate a broad population of chemokine recep-
tors, but is most selective for CCR3 and will block HIV-1 infection of
cells in which CCR3 is present. Moreover, it has been suggested that
vMIP-II might act as a chemokine antagonist in some cases. Other
viruses including HHV-6, murine cytomegalovirus and molluscum
contagiosum virus types 1 and 2, also seem to encode chemokine-like
molecules that could function as chemokine agonists or antagonists,
or both
i. Interestingly, although the Epstein–Barr virus (HHV-4) does
not actually encode chemokines or their receptors within its own
genome, one of its major effects is to cause its host cell to increase syn-
thesis of a chemokine receptor (EBI1/CCR7) and also several chemo-
kines
j–l, so that the net result for the cell might be similar. The signal-
ing pathways that viral chemokines and chemokine receptors might
use to produce their proliferative effects could relate to the survival
promoting or pro-apoptotic effects of chemokines and gp120 in
neurons, depending on the pattern of signaling being produced. The
production of viralkines also has further implications. Thus, if mol-
ecules like vMIP-II bind to CCR3, it can be predicted that patients
with Kaposi’s sarcoma or high loads of HHV-8 might be less prone to
develop HIV-1-related problems of the CNS, for example, by virtue
of their ability to block CCR3 on microglia, by direct blocking of
neurons or via other effects on neurons.
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Box 2.Viralkines:virally mediated growth regulators?There are many precedents that
illustrate the consequences of acti-
vating GPCRs on neurons. In par-
ticular, the large number of studies
showing that such receptors can
rapidly regulate synaptic trans-
mission and neuronal excitability
through diverse presynaptic and
postsynaptic mechanisms should be
considered
70. Such effects are often
the result of the direct interaction
of G-protein subunits with ion
channels, but second-messenger-
mediated modulation also occurs
70.
Activation of chemokine receptors
in immune cells by chemokine
agonists or by gp120 triggers a vari-
ety of signaling events (Box 1).
What is the evidence that similar
things also occur in neurons?
Data that illustrate the functional
effects of chemokines on neurons
are very scarce. However, it appears
that activation of neuronal chemo-
kine receptors (for example, in dor-
sal-root ganglion
71, hippocampal
32
and a variety of other neurons
72)
does produce intracellular Ca
21
transients as previously demon-
strated in immune cells (Box 1, Figs
1 and 2). Furthermore, activation
of chemokine receptors produces
presynaptic inhibition of excitatory
synaptic transmission in cultures of
rat hippocampal pyramidal neur-
ons
32, which is associated with the
inhibition of neuronal Ca
21 chan-
nels, a common consequence that
arises from the activation of GPCRs in these neurons
70.
Similar effects have also been observed with gp120,
which produces intracellular Ca
21 transients in a variety
of cultured neurons
24,32,73,74 (Fig. 1). Overproduction of
gp120 also produces alterations in hippocampal syn-
aptic transmission in mouse brain slices
75. Thus, it seems
that activation of neuronal chemokine receptors pro-
duces effects on neurons that resemble those produced
by a large number of other GPCRs.
Activation of GPCRs can also produce changes in
signaling pathways that relate to mitogen-activated pro-
tein (MAP) kinases and associated molecules, which is
certainly true for chemokine receptors in a variety of
cell types
76 (Box 1). Activation of neuronal chemokine
receptors by chemokines produces increases in extra-
cellular-regulated kinase (ERK) activity, without corre-
sponding changes in JUN N-terminal protein kinase
(JNK), stress-activated protein kinase (SAPK) and p38 ac-
tivity
32. Conversely, gp120 activated both ERKs and JNK
(Ref. 63). It has also been demonstrated that activation
of neuronal chemokine receptors produces increases
in the activated form of the transcription factor cAMP-
response-element-binding protein
32. Such data suggest
that, in addition to mediating rapid neuronal signaling
events that regulate synaptic transmission, activation
of neuronal chemokine receptors might also produce
signals that influence neuronal survival and viability
77.
Indeed, interleukin 8 (IL8)
78 and several other chemo-
kines
32 can act as survival factors for hippocampal
neurons under a variety of conditions, and can inhibit
gp120-induced neuronal death
32. It is, therefore, poss-
ible that binding of gp120 to neuronal chemokine re-
ceptors might interfere with the normal survival sig-
nals produced by these molecules or produce their own
aberrant signals that influence survival adversely.
Under some circumstances, the activation of neuronal
chemokine receptors might actually promote apo-
ptosis
79, perhaps indicating that the viability of neurons
is crucially dependent on the balance of chemokine-
induced second-messenger molecules. There are several
possible ways by which activation of neuronal chemo-
kine receptors could block gp120-induced apoptosis.
By analogy with results on immune cells, it is possible
that competition between gp120 and a chemokine such
as stromal-derived factor 1a (SDF1a) for a common re-
ceptor (for example, CXCR4) might be important (Box
1). However, this cannot be the mechanism involved
for chemokines that do not share the same receptor as
gp120 (Refs 32,78). In such instances, it is possible that
the deleterious effects of gp120 are counteracted at the
level of downstream anti-apoptotic signaling events,
perhaps similar to those activated by chemokines in
some immune cells (Box 1). If this is the case, it might
be predicted that chemokines could be involved in
neurodegenerative diseases in addition to AIDS-related
dementia, such as Alzheimer’s disease and amyotrophic
lateral sclerosis (ALS), in which apoptotic neuronal death
also occurs. It is also interesting to note the analogies
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Fig. 2. Effects of chemokines on intracellular Ca
21 levels, [Ca
21]i, in individual acutely isolated neurons from different
areas of the rat brain. The ability of chemokines to induce functional responses in postnatal acutely isolated neurons
from different brain areas indicates a major role for chemokines in brain physiology and pathology. (A) shows the
response of the area postrema to fractalkine (100 nM), (B) shows the response of the nucleus tractus solitarius to 50 nM
SDF1a (stromal-derived factor 1a; see Ref. 71), (C) shows the response of a Purkinje neuron to eotaxin (50 nM) and (D)
shows the response of a hippocampal granule neuron to 50 nM SDF1a. In each case the chemokine is added during the
period indicated by the horizontal bar. (We are grateful to Dr Samantha Gillard for these data.)
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between the anti-apoptotic effects of chemokines in
neurons and the use of chemokines by viruses as an
anti-apoptotic strategy (Box 2).
In summary, therefore, different cells in the brain,
including neurons, astrocytes and microglia, possess a
wide variety of chemokine receptors. Neuronal receptors
could be involved directly in the mechanisms under-
lying gp120-induced neurodegeneration and this could
occur in addition to indirect mechanisms triggered by
gp120 or other HIV-1-related proteins, or both.
Chemokines and brain function
The fact that cells in the brain, and neurons in par-
ticular, seem to possess a wide range of chemokine re-
ceptors raises questions beyond those that relate to their
role in producing HIV-1-associated neuropathology. It
is unlikely that these receptors are merely awaiting the
arrival of the HIV-1 virus and they presumably sub-
serve other functions in the regulation of the nervous
system. It is clear that various chemokines can be syn-
thesized by different types of cells in the brain
32,59,80–86.
This is certainly true for microglia and astrocytes, and
sometimes for neurons as well
32,57,87. Moreover, the
degree of chemokine synthesis has been shown to
change considerably in response to alterations in the
state of the brain, which include HIV-1-related lesions,
traumatic brain injury, ischemia, multiple sclerosis,
Alzheimer’s disease and acute experimental autoimmune
encephomyelitis
35,57,80–86,88,89. Upregulation of chemokine
receptors can also occur
25,57. The production of chemo-
kines under these circumstances might be involved in
mediating inflammatory reactions in the brain that are
associated with such states
87. In addition, however, one
should consider the possibility that production of
chemokines under normal circumstances might be
involved in phenomena such as the control of tem-
perature
90–92, and communication between the immune
system and the CNS (Ref. 92). Chemokine receptors
located in the area postrema
72 (Fig. 2) and other peri-
ventricular organs would be ideally located to subserve
such functions, sensing chemokines in the bloodstream
that are released during immune activity. Examination
of animals in which the genes for these chemokines or
their receptors have been overexpressed or deleted also
suggests they have a possible regulatory role in neur-
onal development
93. Significantly, Zou et al.
93 have
reported gross disruption of the development of the
cerebellum in CXCR4-knockout mice. Nevertheless, the
production and release of chemokines in the brain
under normal or abnormal circumstances would be
expected to alter neuronal function directly through
activation of neuronal chemokine receptors. It is cer-
tainly clear that activation of such receptors can produce
rapid changes in neuronal excitability and synaptic
communication through effects on ion channels and
other key neuronal components
32. As chemokines are
produced by cells such as astrocytes, this might be one
way of subserving glial–neuronal communication.
Concluding remarks
Current research indicates that HIV-1-induced
changes in the brain might involve a variety of pathol-
ogies resulting from several cellular mechanisms. HIV-1-
related proteins, such as gp120, might kill neurons by
direct actions and also by indirect mechanisms through
the release of different neurotoxins. It is becoming clear
that chemokine receptors are widely distributed on
neurons and other types of brain cells. These receptors
might mediate some of the effects of HIV-1 on the
brain and also suggest a wider role for chemokines in
the regulation of neuronal function.
Note added in proof
During the preparation of this review, three more
papers reporting the direct effect of chemokines on
neurons were published
94–96.
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B OOK REVIEWS
Long ago, we all believed that a gap-junction
channel was a gap-junction channel, whether
it was in crayfish axons or mouse heart, liver
or lens. The molecular-biological revolution
has changed all that: not only are there now
more than a dozen cloned mouse genes
belonging to three distinct but only mildly
divergent connexin groups, but invertebrate
gap-junction channels appear to be formed
by an altogether different gene family or
families, newly termed the ‘innexins’.
More recently, it was also believed that
the absence of coupling between cells would
be so devastating that hereditary loss-of-
function gap-junction mutations would be
unlikely to result in nonfatal human disease
and that knockout of genes that encode
connexins would surely be lethal. It is now
known that a range of connexin mutations
underlie a common type of genetic hearing
loss (Cx26 mutations cause hereditary re-
cessive nonsyndromic deafness, reviewed in
chapters by Forge, Willecke and their col-
leagues) and a common type of peripheral
neuropathy (mutant Cx32 leads to X-linked
Charcot–Marie–Tooth disease, reviewed in
chapters by Scherer and Willecke et al.), and
that these mutations are also less-common
causes of lens opacification (mutant Cx46
and Cx50 produce zonular pulverulent cata-
racts, summarized by papers from groups
headed by Gilula, Willecke and Kistler) and
skin disease (caused by mutant Cx31 in
erythrokeratodermia variabilis). Moreover,
mice lacking Cx32, Cx37, Cx40, Cx46 or
Cx50 have normal lifespans, and even mice
that lack Cx43, the major gap-junction
protein in the heart, survive until birth.
The Novartis Foundation Symposium on
gap-junction-mediated intercellular commu-
nication was held a dozen years after the
first connexin cDNAs were cloned and se-
quenced, and this book, which resulted from
this meeting, summarizes selected aspects
of more than a decade of progress in this
field. As indicated by the cover illustration
of interpersonal rather than intercellular
dialogue, this forum provided discussion of
controversial results obtained by different
groups (including the congenital heart defect
associated with phosphorylation site mu-
tations of Cx43) and focused on defining
issues that required additional studies. The
extensive discussion sections following each
chapter reflect what can only have been
lively interactions, spirited and well focused
under the direction of Bernie Gilula; it was
surely a significant meeting that changed the
way in which these workers viewed the
field. It is important that these discussions
be communicated to the rest of the gap-
junction community; in addition, the indi-
vidual book chapters serve as excellent
overviews of the progress that has been
made in understanding the cell biology of
gap junctions (papers on their molecular
biology by Kumar et al., and on trafficking by
Evans and co-workers) and their roles in
development (Anne Warner) and tumori-
genesis (Yamasaki et al.), as well as other
physiological processes. Together with two
other recent reviews of what connexin mu-
tants and knockouts have taught us
1,2, this
volume should be on every gap-junction-
ologist’s bookshelf.
At least 15 rodent gap-junction genes
have now been cloned and sequenced. Each
encodes a distinct gap-junction protein (con-
nexin), all sharing ~50% amino-acid sequence
similarity. Some connexins are more closely
related than others. At first, two gap-junction
families were distinguished and in the past
year a third family has been added, consist-
ing of the neuron-specific connexins (Cx36
in mammals, Cx35 and Cx34.7 in fish). Two
nomenclatures have been used to distin-
guish the connexins: connexin xx, where xx
indicates the molecular weight predicted
for the protein encoded by the sequence,
and lower case Greek letters, designating
closest homology with the prototypes (for
example, a1 andb1, being rodent Cx43 and
Cx32). Not everyone is happy with either
nomenclature
2, and changes will no doubt be
proposed at the International Gap Junction
Meeting in Switzerland in late August (http://
www.physiol.med.uu.nl/gwatt.htm).
Tissue distribution of each connexin has
been mapped, resulting in the surprising
finding that each organ and virtually every
cell type contains more than one connexin
type. In the nervous system, for example,
Cx32 and Cx45 are present in oligodendro-
cytes, Cx30, Cx40, Cx43, Cx45 are found
in astrocytes, and myelinating Schwann cells
contain Cx32, as well as Cx43 and perhaps
others (see the chapter by Nadarajah and
Parnavelas). At the time of the Novartis
meeting, Cx26, Cx32 and Cx43 had all been
suggested to contribute to coupling be-
tween neurons (chapters by Nadarajah and
Parnavelas, and Vaney), but a major dis-
covery in the intervening year has been a
neuron-specific connexin. First identified
as Cx35 in an elasmobranch
3 and then as
the related Cx35 and Cx34.7 in teleost
4,
rodent Cx36 is found in retina and some
brain neurons
5,6. Because Cx36 is found in
neuronal populations, and its presence peaks
at times when electrical and dye coupling
have been found to be strongest, it seems
likely that this might at long last be the
channel-forming protein that links retinal
ganglion cells to their central targets, and
that forms the electrical synapses between
neurons of the inferior olive, hippocampus
and dentate gyrus.
Most of the genes encoding the con-
nexins have now been expressed in exogen-
ous systems (cRNAs injected into paired
Xenopus oocytes or cDNAs transfected
into mammalian cells), revealing that each
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